Model Informed Drug Development Archives | Certara

Dizal Pharma

Case Study

Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…

CertaraOctober 2, 2025

Conference

37th Annual Meeting of the Southern California Chapter Society of Toxicology (SCCSOT)

CertaraSeptember 22, 2025

Announcement

Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool

RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…

CertaraSeptember 17, 2025

Guide

The Top 10 Things You Need to Know About ADNCA Datasets

Learn how ADNCA datasets can modernize non-compartmental analysis: enhanced compliance, automations, and faster PK data…

CertaraSeptember 11, 2025

Conference

Redefining Every Stage of Investment (RESI) Seed to Exit

CertaraSeptember 5, 2025

Conference

The Pharmacometrics Africa Conference 2025 (PMXAC-2025)

CertaraSeptember 4, 2025

Live Events

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

CertaraSeptember 4, 2025

Webinar

The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape

CertaraSeptember 3, 2025

Webinar

Designing a High-Value Drug Development Program: From Concept to First-in-Human (FIH)

Danielle PillsburyAugust 29, 2025

On-Demand Webinar

Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value

Discover strategies to cut risk, speed timelines, and boost investor confidence in early biotech development.

CertaraAugust 21, 2025

© 2025 Certara. All Rights Reserved. | Legal | Privacy policy